Business
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology
About this update from Abivax Sa
[{"type":"image","alt":"Abivax","displaySize":"","headline":null,"caption":"Abivax","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/v57CPS2C3Q2FJGKeA0P43g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0044215fa29748cca33ccfeb49550e73","width":300,"height":44}},"lazy":false},{"type":"text","content":"Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones","length":108,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, France","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Phase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025","length":143,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":218,"olType":false},{"type":"text","content":"PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that the upcoming Annual General Meeting will be held on June 6, 2025, in Paris, France.","length":454,"tagName":"p"},{"type":"text","content":"Additional information and preparatory documents for this Annual General Meeting will be made available in the coming weeks in accordance with applicable legal and regulatory requirements.","length":188,"tagName":"p"},{"type":"text","content":"This announcement comes as Abivax continues to execute against critical 2025 operational milestones, including the ongoing Phase 3 ABTECT clinical program. The Company confirmed that it remains on track to complete induction trials enrollment in the second quarter of 2025, with top-line induction data expected in the third quarter of 2025.","length":341,"tagName":"p"},{"type":"text","content":"Marc de Garidel, Chief Executive Officer of Abivax, commented: "With major clinical readouts approaching, we b...